Hexagon Nutrition Limited to Review September Results Nov 14

Hexagon Nutrition Limited will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, at its board meeting on November 14, 2026, with an analyst call set for November 18. The review is material because it will provide the company’s next formal update on operating and financial performance.

When will Hexagon Nutrition review its September 2026 results?

Hexagon Nutrition will hold its board meeting on November 14, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026. The agenda, disclosed to the stock exchanges, also includes other business matters.

The results are to cover both standalone and consolidated financial statements. This distinction matters because standalone numbers reflect the listed company’s own operations, while consolidated numbers include financial information from entities required to be consolidated under applicable accounting standards.

The company’s disclosures refer to the September 30 reporting period as the second quarter and first half of FY27. Investors will therefore receive figures covering both the three-month period and the six months from the start of the financial year.

An earlier board-meeting-related reference in the supplied material mentions September 14, 2026. However, the latest board meeting intimation identifies November 14, 2026 as the scheduled date for considering the unaudited September-quarter and half-year results. The November 14 date is the relevant announced date for the upcoming results review.

Why is the trading window closed for Hexagon Nutrition insiders?

Hexagon Nutrition has closed its trading window for directors, officers, designated persons and their immediate relatives from October 1, 2026, until 48 hours after declaration of the September-quarter financial results. The restriction was disclosed under the company’s insider-trading code and the SEBI (Prohibition of Insider Trading) Regulations, 2015.

A trading-window closure is a standard compliance measure used during a period when designated insiders may have access to unpublished price-sensitive information. It does not itself indicate an expected financial outcome, but prevents covered persons from dealing in the company’s securities during the stipulated period.

The closure continues beyond the board meeting until 48 hours after the results are declared and made available. This gives the market time to receive and assess the disclosed financial information before designated insiders may resume trading, subject to the company’s applicable policies.

The company had separately communicated that the date of the board meeting to consider the September 2026 results would be informed in compliance with listing requirements. The November 14 intimation now provides that date and the scope of the financial review.

What financial trends were reported by Hexagon Nutrition earlier?

Hexagon Nutrition’s supplied market data showed revenue from operations of Rs 104.31 crore and net profit of Rs 8.07 crore in Q2 FY26. Revenue was reported as 9.33% lower and net profit as 25.96% lower than in Q1 FY26, while the share price was stated to have declined 0.26% to Rs 65.49 following that update.

For the trailing twelve months ended FY26, the company reported revenue from operations of Rs 324.93 crore, up 9.14% from the previous trailing period. Net profit was Rs 24.38 crore, a 99.67% increase, while EBITDA was Rs 34.51 crore, up 1,728%, and profit before tax was Rs 33.72 crore, up 72.92%.

These figures provide historical context only and do not establish the expected performance for the September 2026 quarter. The November 14 board meeting is intended to approve the relevant unaudited results, which will provide the current-period numbers for comparison.

The company also held its 33rd annual general meeting on September 22, 2026, through video conferencing and other audio-visual means. Shareholders approved, with the requisite majority, the adoption of standalone and consolidated financial statements for FY26 and the declaration of a dividend for the year ended March 31, 2026.

What are the key dates and disclosures for investors?

The key disclosed dates are the October 1, 2026 start of the trading-window closure, the November 14 board meeting and the November 18 analyst and institutional investor conference call at 4:00 p.m. IST. The call is scheduled to discuss operational and financial performance for the quarter and half year ended September 30, 2026.

The November 18 call gives analysts and institutional investors an opportunity to seek management’s explanation of the released results and operating performance. The supplied disclosure confirms the timing and purpose of the call, but does not provide management guidance, earnings estimates or a planned capital-allocation announcement.

The source material also notes that a dividend, bonus issue or stock split, if approved by a board, is subsequently reflected on the corporate-actions page with an ex-date and record date. No such proposal forms part of the stated November 14 agenda, and no new corporate action should be inferred from the results-meeting notice.

How does the results review matter to Hexagon Nutrition investors?

The November 14 review matters because the approved results will be the company’s formal financial update for Q2 and H1 FY27. Investors can use the disclosed revenue, profitability and operating details to assess performance against the earlier FY26 trailing-period figures and the reported Q2 FY26 sequential movement.

The trading restriction supports equal dissemination of material financial information, while the scheduled conference call creates a defined forum for post-results discussion. Until the board releases the results, the filing only confirms the meeting, the reporting period, the restricted trading window and the timing of the investor call.

Conclusion

Hexagon Nutrition is scheduled to consider its unaudited September 2026 quarter and half-year results on November 14, followed by an analyst call on November 18. The announced process follows the company’s insider-trading controls, with the trading window closed from October 1 until 48 hours after the results are declared.

Investors should watch for the standalone and consolidated revenue, profit and operating disclosures released after the board meeting, as well as management commentary during the November 18 call. The company has not disclosed a dividend, bonus issue, split, earnings guidance or other specific corporate action as part of the November 14 agenda.